Jordan S. Orange, MD, PhD Returns to Leadership Role at CHOP
Jordan S. Orange, MD, PhD Takes on New Role at CHOP
Dr. Orange will focus on transformative care and meaningful innovation.
Children's Hospital of Philadelphia (CHOP) has announced that Jordan S. Orange, MD, PhD has rejoined the institution as Pediatrician-in-Chief and Chair of the Department of Pediatrics. In this significant role, he will enhance the pediatric healthcare landscape with a focus on innovation in patient care.
Dr. Orange is an esteemed physician-scientist known for his contributions to understanding pediatric primary immunodeficiencies and the immunobiology of natural killer cells. He completed his pediatric residency at CHOP and previously held the Jeffrey Modell Endowed Chair of Immunology Research, highlighting his remarkable commitment to pediatric healthcare.
Joseph W. St. Geme III, MD, Physician-in-Chief at CHOP, expressed excitement about Dr. Orange's return, stating, "We are thrilled that Dr. Orange has rejoined CHOP. His unparalleled expertise combines clinical and research excellence, which I believe will significantly advance patient care and scientific discovery at our institution.”
Prior to rejoining CHOP, Dr. Orange served as the Reuben S. Carpentier Professor and Chair of the Department of Pediatrics at Columbia University, where he also held the position of Physician-in-Chief at New York Presbyterian Morgan Stanley Children's Hospital. His experience also includes significant roles at Baylor College of Medicine, where he contributed as Professor, Vice Chair for Research, and Chief of Immunology/Allergy/Rheumatology. His leadership at the Center for Human Immunobiology at Texas Children's Hospital showcases his extensive background in healthcare leadership.
Dr. Orange's research career stands out, having made pivotal contributions to immunology. His work has illuminated intercellular immune interactions and the nature of immune diseases through critical insights gained from studying inborn errors of immunity. Notably, he has contributed to the identification of 29 novel genetic diseases that emerged from his laboratory. His dedication to advancing the field is underscored by consistent NIH funding and an impressive portfolio of over 350 publications, leading to a remarkable h-index of 96.
In his own words, Dr. Orange stated, "Advancing our work at CHOP is a profound honor. I am thrilled to be back in this exceptional environment, where our unparalleled infrastructure and unique expertise in rare disease care allow us to potentially redefine success in children's health.”
He completed his academic journey with a baccalaureate and MD/PhD from Brown University, followed by a pediatric residency at CHOP and an Allergy/Immunology/Rheumatology fellowship at Boston Children's Hospital. His accolades include several prestigious awards such as the Judson Daland Prize and the E. Mead Johnson Award, accentuating his contributions to pediatric medicine.
About Children's Hospital of Philadelphia
Children's Hospital of Philadelphia is a renowned non-profit hospital founded in 1855, recognized as the first pediatric hospital in the United States. CHOP is dedicated to delivering exceptional patient care, educating the next generation of providers, and engaging in major research initiatives that have led to remarkable advances benefitting children all over the world. Hosting one of the largest pediatric research programs nationally, the hospital is also known for its extensive CHOP Care Network, providing advanced care through more than 50 practices and specialized centers across several regions.
The institution also operates vital facilities like the Middleman Family Pavilion and its Behavioral Health and Crisis Center, ensuring comprehensive care for pediatric patients. With a strong focus on family-centered care and advocacy, CHOP remains a leading force in promoting children's health and well-being.
Contact: Ashley Moore
Children's Hospital of Philadelphia
267-426-6071
Frequently Asked Questions
What is Dr. Jordan S. Orange's new role at CHOP?
Dr. Orange has rejoined CHOP as Pediatrician-in-Chief and Chair of the Department of Pediatrics.
What are Dr. Orange's notable contributions to immunology?
He has made significant advancements in understanding pediatric primary immunodeficiencies and has played a crucial role in discovering novel genetic diseases.
What educational background does Dr. Orange have?
Dr. Orange completed his MD/PhD at Brown University and his pediatric residency at CHOP.
What accolades has Dr. Orange received?
Dr. Orange has received various prestigious awards, including the Judson Daland Prize and the E. Mead Johnson Award.
What is CHOP's commitment to pediatric healthcare?
CHOP is dedicated to providing exceptional patient care, education for future healthcare professionals, and pioneering research initiatives for children's health improvement.
About The Author
Contact Henry Turner privately here. Or send an email with ATTN: Henry Turner as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.